Platelet-Rich plasma as a symptom- and disEaSe-modifying Treatment fOR knee ostEoarthritis (RESTORE)
|Professor Kim Bennellfirstname.lastname@example.org||+ 61 3 834 44135||View page|
Knee osteoarthritis (OA) is a major public health problem worldwide with no cure. Thus safe and effective treatments that reduce symptoms and slow structural disease progression are needed. While no disease-modifying agent has been approved to date, platelet-rich plasma (PRP), an autologous blood product that contains an elevated concentration of platelets, has biologic potential. However, there is a paucity of randomized controlled trials in knee OA, with those available at high risk of bias, and none investigating the structural effects of PRP.
This novel study will provide high-quality evidence to ascertain whether or not PRP is beneficial for treating knee OA and will inform clinical guidelines. This is important given the cost of PRP treatment, "hype" around the therapy, and increasing clinical use of PRP for knee OA without definitive evidence of benefit. If PRP is found to be symptom- and disease-modifying, this will have a substantial immediate impact on OA management worldwide with major implications for reducing the OA burden. If not, then recommendations against its use can be made.
This study aims to find out whether a series of three PRP injections (one per week for three weeks) into the knee joint is effective in reducing pain and slowing loss of cartilage in the knee joint. To do this, we will compare outcomes over 12 months in a group of patients with knee osteoarthritis who receive three PRP injections and a group who receive three injections of inactive sterile salt injections (saline).
We will recruit 288 people with mild to moderately severe knee osteoarthritis from the community. Measurements will be taken at baseline, 2 months and 12 months and will comprise questionnaires and magnetic resonance imaging. Participants will be randomly allocated to either the PRP or saline injection group and neither the participant nor the injecting doctor will know which injection the participant will receive.
To register your interest as a participant, please click here
- Prof Rachelle Buchbinder
- Dr Yuanyuan Wang
- Prof Andrew Forbes
- Dr Jessica Kasza
- Prof Flavia Cicuttini
- Prof Anthony Harris
Royal North Shore Hospital
- Prof David Hunter
Imaging @ Olympic Park
- A/Prof David Connell
- Dr James Linklater
NMHRC Project Grant; $1,400,359.20
Faculty Research Themes
School Research Themes
For further information about this research, please contact the research group leader.